The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
about
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complicationsCatechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's diseaseEntacapone in the management of Parkinson's disease.5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month studyUpdate on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Levodopa delivery systems: advancements in delivery of the gold standard.Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).Levodopa/carbidopa/entacapone in Parkinson's disease.Bimodal administration of entacapone in Parkinson's disease patients improves motor control.Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.
P2860
Q24234273-D1C62A64-CB02-4A1D-A4A9-F49699BA3903Q24245911-44F5D042-D774-473E-81A7-549969B54617Q34706933-393EAB6B-E0C6-4B77-9980-C256164E4835Q35015786-98EC99D0-F1EB-44D1-9028-93CB8612E58DQ35475549-4099D0DB-876F-42D6-957C-F334983D5854Q36484966-4D73DFB8-07F6-4843-A041-228DA58D2BD7Q37115650-533A465D-A766-4691-B07F-0156ECA279EDQ37679951-DC5E2615-1FE5-4B00-B517-2F2EF86C8EF7Q42427666-FF8E92AF-6827-4405-9DE3-6D474D36B1B5Q43193465-8C488495-ECF8-4298-8ADA-E50C9CA45916Q43951950-83DE27C1-FEEB-4304-8505-71BA79D945DDQ45934197-AD47CA92-1489-4B3E-839A-5FCE59C873D3Q46741012-7F089D7C-6C7D-4936-8613-59B19B8D3757Q50483266-2CBF5F65-66B7-4CB7-BAE1-CF3C7BE46B9B
P2860
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The catechol-O-methyltransfera ...... emet CR in Parkinson's disease
@ast
The catechol-O-methyltransfera ...... emet CR in Parkinson's disease
@en
type
label
The catechol-O-methyltransfera ...... emet CR in Parkinson's disease
@ast
The catechol-O-methyltransfera ...... emet CR in Parkinson's disease
@en
prefLabel
The catechol-O-methyltransfera ...... emet CR in Parkinson's disease
@ast
The catechol-O-methyltransfera ...... emet CR in Parkinson's disease
@en
P2093
P2860
P356
P1476
The catechol-O-methyltransfera ...... emet CR in Parkinson's disease
@en
P2093
P2860
P304
P356
10.1136/JNNP.68.5.589
P407
P577
2000-05-01T00:00:00Z